Hematology NewsPrecision medicine: A new approach to AML, other blood cancersDecember 12, 2021AMLMyelodysplastic Syndrome
Hematology NewsMyeloid patients respond robustly to Moderna COVID vaccineDecember 12, 2021COVID-19 UpdatesAMLMyelodysplastic Syndrome
Hematology NewsFor leukemias, COVID-19 death risks tied to poor prognoses, ICU deferralsDecember 11, 2021ALLCOVID-19 UpdatesMyelodysplastic SyndromeAML
Phase 3 fails to demonstrate survival benefit with tipifarnib maintenance in AML in remissionNovember 30, 2021AML
Alvocidib followed by cytarabine and mitoxantrone shows clinical activity in MCL-1-dependent R/R AMLNovember 30, 2021AML
ICH affects survival in nonpromyelocytic AML patients receiving intensive chemotherapyNovember 30, 2021AML
Antimicrobial prophylaxis prevents life-threatening infections in children with AML receiving chemotherapyNovember 30, 2021AML
New insights on OCV-501 induced immune response and survival in elderly AML patients in CR1November 30, 2021AML
Newly diagnosed AML: Optimization of idarubicin and cytarabine induction based on D5-PBCRNovember 30, 2021AML
AML: Similar posttransplant short-term outcomes after azacitidine-venetoclax vs. intensive chemotherapyNovember 30, 2021AML
Outpatient neutropenia management appears possible without excess risk in pediatric AMLNovember 30, 2021AML
Newly diagnosed mutant-IDH2 AML: Enasidenib + azacitidine fares better than azacitidine in phase 2November 30, 2021AML
